A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Radiation: Conventional radiation therapyRadiation: Hypo-fractioned radiation therapy
- Registration Number
- NCT04658862
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 518
- Ineligible for or have elected not to undergo radical cystectomy
- All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade less than (<) 2 prior to randomization
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- Thyroid function tests are within the normal range per investigator assessment (or stable on hormone supplementation). Investigators may consult an endocrinologist for participant eligibility assessment in the case of equivocal or marginal test results
- Adequate bone marrow, liver, and renal function: Bone marrow function (without the support of cytokines or erythropoiesis-stimulating agent in preceding two weeks): Absolute neutrophil count (ANC) greater than or equal to (>=) 1,500/cubic millimeters (mm^3); Platelet count >=80,000/mm^3; Hemoglobin >=9.0 grams per deciliter (g/dL); Liver function: (Total bilirubin less than or equal to (<=) 1.5 * upper limit of normal (ULN) or direct bilirubin <= ULN for participants with total bilirubin levels greater than (>)1.5*ULN (except participants with Gilbert's Syndrome, who must have a total bilirubin < 3.0 mg/dL), and Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to (<=) 2.5* institutional ULN); Renal function: Creatinine clearance >=30 mL/min using the Cockcroft-Gault formula. 24-hour creatinine clearance test will also be accepted for estimating renal function in situations where Cockcroft-Gault formula is not a good predictor of estimating adequate renal function
- Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder. Ta/T1/Carcinoma in situ (CIS) of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to initiating study
- Must not have diffuse CIS based on cystoscopy and biopsy. Diffuse, or multi-focal, CIS is defined as the presence of at least 4 distinct CIS lesions in the bladder at the time of the Screening re-TURBT
- Participants must not have evidence of cT4b, or N1-3, or M1 disease based on local radiology staging (chest, abdomen, and pelvis must be performed using Computed tomography [CT] or Magnetic resonance imaging [MRI]) within 42 days prior to randomization
- Presence of any bladder or urethral anatomic feature that, in the opinion of the investigator, may prevent the safe placement, indwelling use, or removal of TAR 200
- Evidence of bladder perforation during diagnostic cystoscopy. Participant is eligible if perforation has healed prior to randomization
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description TAR-200 + Cetrelimab Cetrelimab Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with intravenous (IV) Cetrelimab. TAR-200 + Cetrelimab TAR-200 Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with intravenous (IV) Cetrelimab. Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy Cisplatin Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 4 to 6 treatment weeks or gemcitabine intravenously twice weekly for 4 to 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray \[Gy\], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks. Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy Gemcitabine Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 4 to 6 treatment weeks or gemcitabine intravenously twice weekly for 4 to 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray \[Gy\], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks. Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy Conventional radiation therapy Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 4 to 6 treatment weeks or gemcitabine intravenously twice weekly for 4 to 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray \[Gy\], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks. Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy Hypo-fractioned radiation therapy Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 4 to 6 treatment weeks or gemcitabine intravenously twice weekly for 4 to 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray \[Gy\], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks.
- Primary Outcome Measures
Name Time Method Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event Up to 8 years Time from randomization to the first BI-EFS event includes histologically proven presence of muscle-invasive bladder cancer (MIBC), clinical evidence of nodal or metastatic disease (as assessed by RECIST 1.1 criteria), radical cystectomy (RC), or death due to any cause.
- Secondary Outcome Measures
Name Time Method Metastasis-free survival (MFS) Up to 8 years MFS is measured from time from randomization to first radiologic (as assessed by RECIST 1.1 criteria) evidence of metastatic disease or death due to any cause.
Overall Survival (OS) Up to 8 years OS is defined as time from randomization to death.
Overall Response Rate (ORR) Up to 8 years ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR). CR is defined as Negative biopsy, and Computed tomography/Magnetic resonance imaging (CT/MRI) showing no evidence of locally advanced or metastatic disease. PR (down-staging) is defined as biopsy proven non-muscle invasive disease (Ta, T1, Tis) and CT/MRI showing no evidence of locally advanced or metastatic disease. Non-Response (NR) includes those not achieving a CR or PR. Those who do not undergo a biopsy will be considered Non-Evaluable (NE).
Number of Participants with Adverse Events (AEs) According to Common Terminology Criteria for Adverse Events (CTCAE) Up to 8 years Number of Participants with AEs by Severity as assessed by CTCAE version 5 will be reported. Grade refers to the severity of the AE as follows: Grade 1- Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2- Moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3- Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care ADL; Grade 4- Life-threatening consequences, urgent intervention indicated; Grade 5- Death related to AE.
Number of Participants with AEs by Severity according to Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE) Up to 8 years NCI PRO-CTCAE is a patient-reported item library used to evaluate symptomatic treatment-emergent adverse events in participants on cancer clinical trials. The items selected for this study include all NCI PRO-CTCAE gastrointestinal items and urinary items. These items include taste changes, decreased appetite, nausea, vomiting, heartburn, gas, bloating, hiccups, constipation, diarrhea, abdominal pain, fecal incontinence, painful, urination, urinary urgency, urinary frequency, change in usual urine color, and urinary incontinence.
Number of Participants with Clinical Laboratory Abnormalities Up to 8 years Number of participants with clinical laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
Trial Locations
- Locations (290)
Aakash Healthcare Super Speciality Hospital
🇮🇳New Delhi, India
Instituto Medico Especializado Alexander Fleming
🇦🇷Buenos Aires, Argentina
Fundação Hospitalar São Francisco de Assis
🇧🇷Belo Horizonte, Brazil
Centre Hospitalier Prive
🇫🇷Saint-Grégoire, France
Hopital Foch
🇫🇷Suresnes, France
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
SLK-Kliniken Heilbronn - Klinikum am Gesundbrunnen
🇩🇪Heilbronn, Germany
Klinikum Herne - Urologie
🇩🇪Herne, Germany
Matthias Schulze - Germany
🇩🇪Markkleeberg, Germany
Universitatsklinikum Munster
🇩🇪Münster, Germany
Klinikum Nürnberg Nord - Hautklinik
🇩🇪Nürnberg, Germany
Krankenhaus der Barmherzigen Bruder Trier
🇩🇪Trier, Germany
Alexandra General Hospital of Athens
🇬🇷Athens, Greece
Metropolitan General A E
🇬🇷Holargos, Greece
Athens Medical Center
🇬🇷Maroussi, Greece
Bioclinic - Thessaloniki
🇬🇷Thessaloniki, Greece
Euromedica General Clinic
🇬🇷Thessaloniki, Greece
Clinic Agios Loukas
🇬🇷Thessaloniki, Greece
Papageorgiou General Hospital Of Thessaloniki
🇬🇷Thessaloniki, Greece
Anassa General Clinic
🇬🇷Volos, Greece
Orszagos Onkologiai Intezet
🇭🇺Budapest N/a, Hungary
Eszak Pesti Centrumkorhaz Honvedkorhaz
🇭🇺Budapest, Hungary
Bajcsy-Zsilinszky Kórház és Rendelőintézet
🇭🇺Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont
🇭🇺Debrecen, Hungary
Rajiv Gandhi Cancer Institute & Research Centre
🇮🇳New Delhi, India
Indira Gandhi Institute of Medical Sciences
🇮🇳Patna, India
Jehangir Clinical Development Center Pvt Ltd
🇮🇳Pune, India
Ospedale San Donato
🇮🇹Arezzo, Italy
Fondazione del Piemonte per I Oncologia IRCC Candiolo
🇮🇹Candiolo, Italy
Ospedale Civile Ramazzini
🇮🇹Carpi, Italy
Ospedale Umberto I di Lugo
🇮🇹Lugo, Italy
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Ospedale San Raffaele
🇮🇹Milan, Italy
Azienda Ospedaliera Universitaria Federico II
🇮🇹Napoli, Italy
Istituto Oncologico Veneto - IRCCS
🇮🇹Padova, Italy
Azienda Sanitaria Locale Salerno - Po Andrea Tortora Di Pagani
🇮🇹Pagani, Italy
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
ASL Napoli 2 Nord-SM delle Grazie Hospital
🇮🇹Pozzuoli, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Italy
Azienda Ospedaliera Sant Andrea
🇮🇹Roma, Italy
Universita Campus Bio-Medico di Roma
🇮🇹Rome, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Rome, Italy
Istituto Clinico Humanitas Rozzano, IRCCS
🇮🇹Rozzano, Italy
Michigan Institute of Urology
🇺🇸Troy, Michigan, United States
Centro Hospitalar de Lisboa Central
🇵🇹Lisboa, Portugal
H. Santa Maria - Centro Hospitalar de Lisboa Norte
🇵🇹Lisboa, Portugal
Fund. Champalimaud
🇵🇹Lisbon, Portugal
Hospital de Sao Joao
🇵🇹Porto, Portugal
Fund. Puigvert
🇪🇸Barcelona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp. Univ. Virgen de Las Nieves
🇪🇸Granada, Spain
Hosp. de Jerez de La Frontera
🇪🇸Jerez de la Frontera, Spain
Clinica Univ. de Navarra
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. de La Paz
🇪🇸Madrid, Spain
Hosp Univ Hm Sanchinarro
🇪🇸Madrid, Spain
Corporacio Sanitari Parc Tauli
🇪🇸Sabadell, Spain
Hosp. Univ. Marques de Valdecilla
🇪🇸Santander, Spain
Instituto Valenciano de Oncologia
🇪🇸Valencia, Spain
Hosp. Clinico Univ. de Valencia
🇪🇸Valencia, Spain
Asklepion LLC
🇺🇦Kiev, Ukraine
Kyiv City Clinical Hospital #3
🇺🇦Kyiv, Ukraine
State Institution Academy Of Medical Sciences Of Ukraine
🇺🇦Kyiv, Ukraine
ZNA Middelheim
🇧🇪Antwerpen, Belgium
AZ Sint-Lucas
🇧🇪Assebroek, Belgium
AZ Sint Jan Brugge Oostende AV
🇧🇪Brugge, Belgium
Az Groeninge
🇧🇪Kortrijk, Belgium
Algemeen Ziekenhuis Delta
🇧🇪Roeselare, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
Centro de Urologia (CDU)
🇦🇷Ciudad Automoma Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
🇦🇷Ciudad Autónoma De Buenos Aires, Argentina
Centro Urologico Profesor Bengio
🇦🇷Cordoba, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
🇦🇷Córdoba, Argentina
Sanatorio Allende Cerro
🇦🇷Córdoba, Argentina
Centro Oncologico Riojano Integral (Cori)
🇦🇷La Rioja, Argentina
Liga Paranaense de Combate ao Cancer
🇧🇷Curitiba, Brazil
Centro Regional Integrado de Oncologia CRIO
🇧🇷Fortaleza, Brazil
Clinica de Oncologia Reichow
🇧🇷Jardim Blumenau, Brazil
Fundacao Doutor Amaral Carvalho
🇧🇷Jau, Brazil
Liga Norte Riograndense Contra O Cancer
🇧🇷Natal, Brazil
Associacao Hospitalar Moinhos de Vento
🇧🇷Porto Alegre, Brazil
Hospital das Clinicas de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hopital Pellegrin CHU Bordeaux
🇫🇷Bordeaux, France
ICH Hopital A. Morvan
🇫🇷Brest, France
Hôpital Côte de Nacre
🇫🇷Caen Cedex 9, France
Pole Sante Leonard de Vinci
🇫🇷Chambray-lès-Tours, France
Clinique Sainte Marguerite
🇫🇷Hyeres, France
CHRU Lille
🇫🇷Lille, France
Polyclinique de Limoges - Francois Chenieux
🇫🇷Limoges, France
Hôpital Edouard Herriot
🇫🇷Lyon Cedex 03, France
Institut Paoli-Calmettes
🇫🇷Marseille, France
Hôpital Européen
🇫🇷Marseille, France
Institut Regional du Cancer de Montpellier
🇫🇷Montpellier, France
CHU Nîmes
🇫🇷Nimes, France
Institut Mutualiste Montsouris
🇫🇷Paris, France
Hopital Europeen Georges-Pompidou
🇫🇷Paris, France
Hôpital Bichat - Claude Bernard
🇫🇷Paris, France
Hopital Tenon
🇫🇷Paris, France
Clinical La Croix Du Sud - Ramsay Santé
🇫🇷Quint-Fonsegrives, France
Centre hospitalier universitaire de St Etienne
🇫🇷Saint-Etienne Cedex 2, France
Institut de Cancerologie de Lorraine
🇫🇷Vandoeuvre les Nancy, France
Gustave Roussy
🇫🇷Villejuif Cedex, France
Klinikum Augsburg
🇩🇪Augsburg, Germany
Staedtisches Klinikum Braunschweig
🇩🇪Braunschweig, Germany
Universitatsklinikum Carl Gustav Carus Dresden
🇩🇪Dresden, Germany
Urologicum Duisburg
🇩🇪Duisburg, Germany
Universitatsklinikum Dusseldorf
🇩🇪Düesseldorf, Germany
Klinik und Poliklinik für Urologie
🇩🇪Essen, Germany
Agaplesion Frankfurter Diakonie Kliniken GmbH, Markus Krankenhaus
🇩🇪Frankfurt Am Main, Germany
Universitatsklinikum Frankfurt
🇩🇪Frankfurt am Main, Germany
Hosp Univ A Coruna
🇪🇸A Coruña, Spain
Loma Linda Univ Faculty Medic
🇺🇸Loma Linda, California, United States
University of Southern California
🇺🇸Los Angeles, California, United States
Providence Saint John s Health Center
🇺🇸Santa Monica, California, United States
Stanford University Medical Center
🇺🇸Stanford, California, United States
The Urology Center of Colorado
🇺🇸Denver, Colorado, United States
Foothills Urology - Golden Off
🇺🇸Golden, Colorado, United States
Boca Raton Regional Hospital
🇺🇸Boca Raton, Florida, United States
Urological Research Network
🇺🇸Hialeah, Florida, United States
Memorial Healthcare System
🇺🇸Pembroke Pines, Florida, United States
Winship Cancer Institute of Emory University
🇺🇸Atlanta, Georgia, United States
DuPage Medical Group
🇺🇸Lisle, Illinois, United States
University Hospitals Seidman Cancer Center
🇺🇸Ann Arbor, Michigan, United States
Adult Pediatric Urology & Urogynecology, P.C
🇺🇸Omaha, Nebraska, United States
Garden State Urology
🇺🇸Morristown, New Jersey, United States
New Jersey Urology LLC
🇺🇸Voorhees, New Jersey, United States
Cardiology Clinic at Montefiore Hutchinson Complex
🇺🇸Bronx, New York, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Vidant Urology - Greenville
🇺🇸Greenville, North Carolina, United States
Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center
🇺🇸Winston-Salem, North Carolina, United States
Wexner Medical Center at the Ohio State University
🇺🇸Columbus, Ohio, United States
Stephenson Cancer Center
🇺🇸Oklahoma City, Oklahoma, United States
MidLantic Urology
🇺🇸Bala-Cynwyd, Pennsylvania, United States
Carolina Urologic Research Center
🇺🇸Myrtle Beach, South Carolina, United States
University of Tennessee Medical Center
🇺🇸Knoxville, Tennessee, United States
Houston Metro Urology
🇺🇸Houston, Texas, United States
University of Texas Medical Branch
🇺🇸League City, Texas, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
Fundacion Intecnus
🇦🇷Bariloche, Argentina
Hosp. Univ. Germans Trias I Pujol
🇪🇸Badalona, Spain
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
🇦🇷Buenos Aires, Argentina
Centro de Investigacion Pergamino SA
🇦🇷Pergamino, Argentina
CEDIC Centro de Investigaciones Clinicas
🇦🇷Viedma, Argentina
Flinders Medical Centre
🇦🇺Bedford Park, Australia
Krankenhaus der barmherzigen Schwestern
🇦🇹Linz, Austria
Universitaetsklinikum Salzburg Landeskrankenhaus
🇦🇹Salzburg, Austria
Medizinische Universitaet Wien
🇦🇹Wien, Austria
Hopital Erasme
🇧🇪Anderlecht, Belgium
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Hospital Regional do Cancer - Hospital de Esperança
🇧🇷Presidente Prudente, Brazil
Hospital Sao Rafael
🇧🇷Salvador, Brazil
CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
🇧🇷Santo Andre, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
🇧🇷Sao Jose do Rio Preto, Brazil
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
🇧🇷Sao Paulo, Brazil
Hospital Alemao Oswaldo Cruz
🇧🇷Sao Paulo, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente de Senhoras - Hospital Sirio Libanes
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
🇧🇷Sao Paulo, Brazil
Centro Oncológico do Triângulo
🇧🇷Uberlândia, Brazil
McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
CHU de Quebec L Hotel Dieu de Quebec
🇨🇦Québec, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke
🇨🇦Sherbrooke, Quebec, Canada
Chinese Academy of Medical Sciences(CAMS) & Peking Union Medical College(PUMC)
🇨🇳Beijing, China
Peking University First Hospital
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
Beijing Hospital
🇨🇳Beijing, China
The First Hospital of Jilin University
🇨🇳Changchun, China
Hunan Cancer hospital
🇨🇳Changsha Shi, China
The Third Xiangya Hospital of Central Sourth University
🇨🇳Changsha, China
West China Hospital of Sichuan University
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Guangzhou First Municipal People's Hospital
🇨🇳Guang Zhou Shi, China
Sun Yat Sen University Cancer Center
🇨🇳Guangzhou, China
Zhejiang Provincial People's Hospital
🇨🇳Hangzhou, China
The First Hospital of Jiaxing
🇨🇳Jiaxing, China
Nanjing Drum Tower Hospital
🇨🇳Nanjing, China
Qingdao Municipal Hospital
🇨🇳Qingdao, China
Ruijin Hospital
🇨🇳Shanghai, China
Renji Hospital
🇨🇳Shanghai, China
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou Shi, China
Wuhan Union Hospital
🇨🇳Wuhan, China
Wuhan Tongji Hospital Tongji Medical College
🇨🇳Wuhan, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Slezska nemocnice v Opave
🇨🇿Opava, Czechia
Fakultni nemocnice Plze
🇨🇿Plzen-Bory, Czechia
Urocentrum Praha
🇨🇿Praha 2, Czechia
Vseobecna fakultni nemocnice v Praze
🇨🇿Praha 2, Czechia
Thomayerova nemocnice
🇨🇿Praha 4, Czechia
Fakultni nemocnice v Motole
🇨🇿Praha 5, Czechia
Nemocnice Na Bulovce
🇨🇿Praha 8, Czechia
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha, Czechia
Metropolitan Hospital
🇬🇷Neo Faliro, Greece
Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
🇭🇺Nyíregyháza, Hungary
Sujan Surgical Cancer Hospital & Amravati Cancer Foundation
🇮🇳Amravati, India
Bangalore Medical College and Research Institute
🇮🇳Bangalore, India
Acharya Tulsi Regional Cancer Treatment Research Institute
🇮🇳Bikaner, India
Shatabdi Super Speciality Hospital
🇮🇳Nashik, India
BLK Super Specialty Hospital
🇮🇳New Delhi, India
Ospedale Cannizzaro
🇮🇹Catania, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia
🇮🇹Foggia, Italy
SPDC Villa Scassi
🇮🇹Genova, Italy
Ospedale San Martino
🇮🇹Genova, Italy
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
🇮🇹Siena, Italy
Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
🇮🇹Torino, Italy
Ospedale di Circolo e Fondazione Macchi
🇮🇹Varese, Italy
Ospedale San Bortolo
🇮🇹Vicenza, Italy
Aso Co.,Ltd Iizuka Hospital
🇯🇵Iizuka, Japan
St Marianna University Hospital
🇯🇵Kanagawa, Japan
Nara Medical University Hospital
🇯🇵Kashihara, Japan
Saitama Medical University Hospital
🇯🇵Kawagoe-Shi, Japan
Kimitsu Chuo Hospital
🇯🇵Kisarazu-shi, Japan
Nagasaki University Hospital
🇯🇵Nagasaki-shi, Japan
JOHAS Osaka Rosai Hospital
🇯🇵Osaka, Japan
Tokuyama Central Hospital
🇯🇵Shunan, Japan
Toranomon Hospital
🇯🇵Tokyo, Japan
Nippon Medical School Hospital
🇯🇵Tokyo, Japan
Fujita Health University Hospital
🇯🇵Toyoake, Japan
Yamaguchi University Hospital
🇯🇵Ube, Japan
Yokohama City University Medical Center
🇯🇵Yokohama, Japan
Inje University Haeundae Paik Hospital
🇰🇷Busan, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Keimyung University Dongsan Hospital
🇰🇷Daegu, Korea, Republic of
Samsung Medical Center
🇰🇷Gangnam Gu, Korea, Republic of
National Cancer Center
🇰🇷Goyang si, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Hwasun-gun, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Namdong, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Gangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Mary s Hospital
🇰🇷Seoul, Korea, Republic of
Hanyang University Hospital
🇰🇷Seoul, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan Si, Korea, Republic of
Oncologia Integral Satelite
🇲🇽Ciudad de México, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽Guadalajara, Mexico
Consultorio Privado Dr Jose Arturo Rodriguez Rivera
🇲🇽Guadalajara, Mexico
Centro De Estudio Y Prevencion Del Cancer
🇲🇽Juchitan De Zaragoza, Mexico
Dr. Marco Antonio Badillo Santoyo
🇲🇽Leon, Mexico
i Can Oncology Center
🇲🇽Monterrey, Mexico
Centro de Investigacion Clinica Chapultepec
🇲🇽Morelia, Mexico
Oaxaca Site Management Organization S.C.
🇲🇽Oaxaca, Mexico
Centro de Investigacion Clinica de Oaxaca
🇲🇽Oaxaca, Mexico
Oncologico Potosino
🇲🇽San Luis Potosi, Mexico
Investigación Biomedica para el desarrollo de Farmacos, S.A. de C.V.
🇲🇽Zapopan, Mexico
Samodzielny Publiczny Szpital Wojewodzki im. Papieza Jana Pawla II
🇵🇱Siedlce, Poland
Centrum Medyczne Pratia Poznan
🇵🇱Skorzewo, Poland
Centralny Szpital Kliniczny MSWiA w Warszawie
🇵🇱Warszawa, Poland
Uniwersytecki Szpital Kliniczny
🇵🇱Wroclaw, Poland
Hospital Garcia de Orta
🇵🇹Almada, Portugal
Centro Hospitalar e Universitario de Coimbra
🇵🇹Coimbra, Portugal
Altlay Regional Oncology Dispensary
🇷🇺Barnaul, Russian Federation
Ivanovo Regional Oncology Dispensary
🇷🇺Ivanovo, Russian Federation
Krasnoyarsk Regional Oncology Dispensary
🇷🇺Krasnoyarsk, Russian Federation
Hertzen Oncology Research Institute
🇷🇺Moscow, Russian Federation
A. Tsyb Medical Radiological Research Center
🇷🇺Obninsk, Russian Federation
BHI of Omsk region Clinical Oncology Dispensary
🇷🇺Omsk, Russian Federation
Ryazan State Medical University named after I.P.Pavlov
🇷🇺Ryazan, Russian Federation
N.N. Petrov Research Institute Of Oncology
🇷🇺Saint Petersburg, Russian Federation
Ogarev Mordovian State University
🇷🇺Saransk, Russian Federation
State Medical Institution Oncological Center #2 of Healthcare Department at Krasnodar Regio
🇷🇺Sochi, Russian Federation
Multifunctional clinical medical center 'Medical city'
🇷🇺Tyumen, Russian Federation
Bashkir State Medical University
🇷🇺Ufa, Russian Federation
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital Linkou Branch
🇨🇳Taoyuan, Taiwan
Adana Baskent Yuregir Hospital
🇹🇷Adana, Turkey
Yildirim Beyazit University Medical Faculty Ankara Atatürk Research and Training Hospital
🇹🇷Ankara, Turkey
Ankara Universitesi Tip Fakultesi Cebeci Hastanesi
🇹🇷Ankara, Turkey
Dokuz Eylul Universitesi Tip Fakultesi
🇹🇷Balcova, Turkey
Bezmialem University Medical Faculty
🇹🇷Fatih, Turkey
Medical Park Gaziantep Hastanesi
🇹🇷Gaziantep, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Istanbul Medeniyet University Goztepe Training and Research Hospital
🇹🇷Istanbul, Turkey
Izmir Medical Park Hospital
🇹🇷Izmir, Turkey
Inonu University Medical Faculty
🇹🇷Malatya, Turkey
Erciyes Univ MKD Hospital
🇹🇷Melikgazi, Turkey
T.C. Saglik Bakanligi Ankara Numune Egitim ve Arastirma Hastanesi
🇹🇷Seyhan, Turkey
Chernihivskyi oblasnyi onkolohichnyi dyspanser
🇺🇦Chernihiv, Ukraine
SE Dnipropetrovsk Medical Academy
🇺🇦Dnipro, Ukraine
Kharkiv Regional Clinical Hospital
🇺🇦Kharkiv, Ukraine
Khersonsky Regional Oncology Center
🇺🇦Kherson, Ukraine
P.L. Shupyk National Medical Academy of Post-Graduate Education
🇺🇦Kyiv, Ukraine
Lviv Regional Clinical Hospital
🇺🇦Lviv, Ukraine